<ul>
	<li>LABA monotherapy increases the risk of serious asthma-related events.</li>
	<li>Do not initiate in acutely deteriorating COPD or asthma. Do not use to treat acute symptoms.</li>
	<li>Do not use in combination with additional therapy containing a LABA because of risk of overdose.</li>
	<li>Candida albicans infection of the mouth and pharynx may occur. Monitor patients periodically. Advise the patient to rinse his/her mouth with water without swallowing after inhalation to help reduce the risk.</li>
	<li>Increased risk of pneumonia in patients with COPD. Monitor patients for signs and symptoms of pneumonia.</li>
	<li>If paradoxical bronchospasm occurs, discontinue and institute alternative therapy.</li>
	<li>Use with caution in patients with cardiovascular disorders because of beta-adrenergic stimulation.</li>
	<li>Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction.</li>
	<li>Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.</li>
</ul>